摘要
目的:比较吸入激素(ICS)联合缓释茶碱(SRT)和吸入双倍剂量ICS对哮喘患者的疗效及不良反应。方法:42例哮喘患者随机分成2组。A组22例,予布地奈得联合SRT 0.2/d;B组予相应级别双倍剂量。疗程6个月。比较治疗前后临床疗效、肺功能及血浆皮质醇浓度的变化。结果:治疗后2组患者症状评分较治疗前明显降低。2组比较无显著差异。治疗前后血浆皮质醇浓度差异无统计学意义。结论:ICS联合SRT和双倍剂量ICS治疗哮喘疗效相当。未见HAPP抑制的不良反应。
Objective： To compare the therapeutic effect of ICS combined with slow release SRT to double dose ICS in asthmatics. Method： 42 asthmatics subjects were randomaly divided into group A and B. 22 cases in group A received 200μg-800μg budesonide （ BUD ） daily with SRT 0.1 twice daily for 6 months. 20 cases received double dose budesonede daily for 6 months. During the six months,FEVl ,PEF, clinical effects, and plasma cortisol level were evaluated. Result： Significant decreases were observed in symptom scores after treatment with ICS plus SRT or double dose of ICS ,however ,no difference between two groups. And no significant change in plasma cortisol level. Conclusion： Both ICS combined with SRT and double dosage of ICS have equivalent effects in relieving symptoms in asthma therapy and it did not induce suppression of HAPP axis function in the patients.
出处
《河北医学》
CAS
2005年第12期1071-1073,共3页
Hebei Medicine
关键词
哮喘
吸入激素
茶碱
Asthma
Inhaled corticosteroid
Thephylline
